Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

NVA237 BID Versus Placebo Twelve-week Efficacy Study

ClinicalTrials.gov ID: NCT01715298

Public ClinicalTrials.gov record NCT01715298. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe. The efficacy and safety of the drug will be tested against a placebo treatment. The primary criterion to assess efficacy will be the difference between the serial lung function measurements of patients who have been treated for 12 weeks with NVA237 versus those that have received placebo treatment for 12 weeks. A serial lung function measurement (FEV1 testing) will be conducted and the "area under the curve" will be the measure for the ability to breathe.

Study identification

NCT ID
NCT01715298
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
432 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2012
Primary completion
Nov 30, 2013
Completion
Nov 30, 2013
Last update posted
Mar 10, 2015

2012 – 2013

United States locations

U.S. sites
59
U.S. states
27
U.S. cities
51
Facility City State ZIP Site status
Novartis Investigative Site *See Various Dept.'s* Arizona
Novartis Investigative Site Chandler Arizona 85224
Novartis Investigative Site Fresno California 93726
Novartis Investigative Site Fullerton California 92835
Novartis Investigative Site Yorba Linda California 92886-7921
Novartis Investigative Site Yorba Linda California 92886
Novartis Investigative Site Boulder Colorado 80304
Novartis Investigative Site Wheat Ridge Colorado 80033
Novartis Investigative Site Lynn Haven Florida 32444
Novartis Investigative Site Miami Florida 33173
Novartis Investigative Site Port Orange Florida 32127
Novartis Investigative Site Winter Park Florida 32789
Novartis Investigative Site Conyers Georgia 30094
Novartis Investigative Site River Forest Illinois 60305
Novartis Investigative Site Skokie Illinois 60076
Novartis Investigative Site Evansville Indiana 47714
Novartis Investigative Site Lexington Kentucky 40509
Novartis Investigative Site Sunset Louisiana 70584
Novartis Investigative Site Fall River Massachusetts 02720
Novartis Investigative Site North Dartmouth Massachusetts 02747
Novartis Investigative Site Minneapolis Minnesota 55402
Novartis Investigative Site Plymouth Minnesota 55441
Novartis Investigative Site Saint Charles Missouri 63301
Novartis Investigative Site St Louis Missouri 63128
Novartis Investigative Site St Louis Missouri 63141
Novartis Investigative Site Fremont Nebraska 68025
Novartis Investigative Site Lincoln Nebraska 68510
Novartis Investigative Site Omaha Nebraska 68114
Novartis Investigative Site Cherry Hill New Jersey 08003
Novartis Investigative Site Albuquerque New Mexico 87108
Novartis Investigative Site Brooklyn New York 11229
Novartis Investigative Site Brooklyn New York 11234
Novartis Investigative Site Great Neck New York 11021
Novartis Investigative Site Massapequa New York 11758
Novartis Investigative Site New Windsor New York 12553
Novartis Investigative Site New York New York 10003
Novartis Investigative Site New York New York 10028
Novartis Investigative Site Charlotte North Carolina 28207
Novartis Investigative Site Cincinnati Ohio 45231
Novartis Investigative Site Cincinnati Ohio 45242
Novartis Investigative Site Cincinnati Ohio 45245
Novartis Investigative Site Columbus Ohio 43213
Novartis Investigative Site Medford Oregon 97504-8741
Novartis Investigative Site Medford Oregon 97504
Novartis Investigative Site Portland Oregon 97213
Novartis Investigative Site Langhorne Pennsylvania 19047
Novartis Investigative Site Pittsburgh Pennsylvania 15243
Novartis Investigative Site Pottstown Pennsylvania 19464
Novartis Investigative Site Tipton Pennsylvania 16684
Novartis Investigative Site East Providence Rhode Island 02914
Novartis Investigative Site Fort Mill South Carolina 29707
Novartis Investigative Site Rock Hll South Carolina 29732
Novartis Investigative Site Denton Texas 76210
Novartis Investigative Site San Antonio Texas 78229
Novartis Investigative Site Midvale Utah 84047
Novartis Investigative Site South Burlington Vermont 05403
Novartis Investigative Site Richmond Virginia 23219
Novartis Investigative Site Richmond Virginia 23233
Novartis Investigative Site Tacoma Washington 98405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01715298, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 10, 2015 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01715298 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →